Table 2.
Median intragastric pH during the first 24 and 48 h with different intravenous infusion regimens as a function of CYP2C19 genotype status.
| Regimen | Periods | RM | IM | PM |
|---|---|---|---|---|
| Placebo | First 24 h | 2.2 (1.3–3.6) | 2.8 (1.8–3.5) | 2.4 (1.5–2.9) |
| First 48 h | 2.1 (1.5–3.4) | 2.8 (1.5–3.9) | 2.4 (1.9–3.3) | |
| Famotidine | First 24 h | 4.4 (3.8–4.9) | 4.1 (3.9–6.5) | 4.7 (3.7–5.7) |
| First 48 h | 4.2 (3.5–4.6) | 4.0 (3.8–6.1) | 4.3 (3.6–4.9) | |
| Omeprazole | First 24 h | 3.9 (2.6–4.7) | 5.8 (4.3–6.3)∗ | 6.1 (5.3–7.4)∗ |
| First 48 h | 4.8 (3.2–5.3) | 6.0 (5.4–6.5)∗ | 6.1 (5.7–7.5)∗ | |
| Concomitant | First 24 h | 4.8 (4.5–5.4) | 5.8 (5.1–6.4)∗ | 5.8 (5.4–6.2)∗ |
| First 48 h | 5.3 (4.7–5.4) | 5.7 (5.5–6.4)∗ | 5.9 (5.5–6.2)∗ |
∗: P < 0.05 (versus RM).